CADL Candel Therapeutics
- 11.480
- -0.790-6.44%
Candel Therapeutics News
Candel Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Schoch Charles
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Chief Technology Officer Tyagarajan Seshu
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Chief Executive Officer Tak Paul Peter
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Nichols William Garrett
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Barone Francesca
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Chief Financial Officer Amello Jason
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Chief Executive Officer Tak Paul Peter
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Chief Technology Officer Tyagarajan Seshu
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Nichols William Garrett
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Barone Francesca
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Chief Financial Officer Amello Jason
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Gaeta Renee
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Nguyen Diem
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Manning Paul B
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Martell Christopher
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Benz Edward J. JR
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director PAPA JOSEPH C
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Aguilar-Cordova Estuardo
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Nabel Gary J.
Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Loggia Nicoletta
Analysis
Price Target
No Data
